Very thankful to Emily Landon, MD, executive medical director of infection prevention and control, University of Chicago, for her sixth appearance on the show to discuss practical considerations for “ramp-up” testing, what a negative test result really means (or does not mean) and how often to repeat the test, updates on data for remdesivir, and more. Dr. Landon has been a returning guest on the podcast helping listeners navigate many uncertainties with this pandemic and answering questions in a very easy way that the common public understand.
Dr Nabhan and Dr Landon have no relevant financial disclosures. Click here to learn more about Emily Landon.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
